Pfizer Earnings Call: Pipeline Strength Amid COVID Reset

Pfizer Inc ((PFE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call

The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying strength and execution despite headline pressures. While total revenue slipped modestly and large non‑cash impairments weighed on GAAP results, the company highlighted better‑than‑expected adjusted earnings, expanding margins for the full year, and accelerating contributions from newly launched and acquired medicines. Executives leaned heavily on a clear strategic story—shifting away from COVID dependence, driving cost savings, scaling AI, and reinvesting in high‑impact R&D—arguing that these positives outweigh near‑term headwinds from declining COVID sales and upcoming loss‑of‑exclusivity (LOE) events.

Beating Earnings Expectations While Rewarding Shareholders

Pfizer reported full‑year 2025 adjusted diluted EPS of $3.22, up from $3.11 in 2024 and ahead of market expectations, underscoring disciplined cost control and operational efficiency even in a flat-to-down top‑line environment. The company paired this with sizable capital deployment: $9.8 billion was returned to shareholders through dividends, while $10.4 billion was invested in internal R&D and roughly $8.8 billion in business development. For investors, this mix signals a dual focus on near‑term shareholder returns and longer‑term growth, even as the company navigates a volatile earnings backdrop.

Non‑COVID Portfolio Shows Solid Underlying Growth

Beneath the headline revenue decline, Pfizer’s core non‑COVID business delivered healthy expansion. Excluding COVID‑19 products, full‑year 2025 operational revenue grew 6%, indicating a steady build in the base portfolio. In Q4 specifically, non‑COVID product revenue rose 9% operationally versus the prior year, highlighting momentum across key therapeutic areas. This divergence between shrinking COVID sales and a growing non‑COVID franchise is central to Pfizer’s investment case as the company works to rebase and stabilize its revenue profile.

New and Acquired Products Emerging as Growth Engine

Recently launched and acquired products were a standout driver, generating $10.2 billion in 2025 revenues and growing approximately 14% operationally year‑over‑year. Management framed this cohort as the main engine of Pfizer’s post‑COVID transformation, with contributions spanning oncology, neurology, and other specialty areas. The strong uptake suggests that recent acquisitions and launches are beginning to offset revenue erosion elsewhere in the portfolio, a key factor in supporting medium‑term growth expectations.

Margin Expansion and Cost‑Savings Efforts Gain Traction

Despite revenue pressures, Pfizer delivered notable profitability gains for the full year, with adjusted gross margin expanding to 76%. Cost‑savings initiatives—particularly within manufacturing—are already flowing through the P&L: roughly $600 million in savings were realized from phase one of the manufacturing optimization program through 2025. The company expects total manufacturing savings of $1.5 billion by 2027, adding to broader productivity and cost‑realignment targets. However, Q4 highlighted some variability, as margins compressed on less favorable product mix.

Obesity Candidate Metsera (PF‑3944) Delivers Competitive Early Data

One of the most closely watched updates came from Pfizer’s obesity program, particularly its Metsera (PF‑3944) candidate with monthly dosing. In the VESPER (VESPA) study, placebo‑adjusted weight loss reached 10.0%–12.3% at week 28 for low and medium monthly maintenance doses, with modeling projecting around 16% at week 28 for the high 9.6 mg monthly dose. The safety profile was described as favorable, dominated by mild to moderate gastrointestinal side effects and low discontinuation rates. For investors tracking the obesity space, these data suggest a potentially differentiated profile, especially around dosing convenience, in an increasingly competitive therapeutic category.

Pipeline Activity Accelerates Across Key Therapeutic Areas

Pfizer underscored the breadth of its R&D engine, noting that 2025 delivered 40 approvals or critical readouts and the initiation of 11 pivotal studies. Looking ahead, the company expects roughly 20 pivotal studies in 2026, about half of them in the Metsera obesity portfolio, alongside important readouts in oncology and vaccines. This level of pipeline throughput is central to management’s message that future growth will be driven by innovation, helping to offset patent expiries and declining COVID revenues.

Commercial Leadership in Migraine and Bladder Cancer

On the commercial front, Pfizer flagged strong competitive positions in several key markets. In migraine, Nurtec captured 83% of new CGRP writer volume in Q4 and led new patient starts in the oral CGRP class, underscoring its brand strength and prescriber preference. In oncology, PADCEV (PATCEV) secured an FDA approval in a new muscle‑invasive bladder cancer indication. If additional approvals follow, management believes the U.S. addressable population could expand by approximately 22,500 patients, opening a meaningful incremental revenue opportunity in a high‑value segment of the oncology market.

Scaling AI as a Productivity and Efficiency Lever

Pfizer is aggressively scaling artificial intelligence across the organization, expanding its compute capacity to more than 1,200 GPUs and embedding AI into discovery, development, manufacturing, and commercial operations. Management cited AI as a contributor to both manufacturing and commercial efficiency gains, suggesting tangible benefits in cycle times and cost per asset. For investors, this push indicates Pfizer is aiming to structurally improve productivity, enhance R&D hit rates, and manage operating expenses in a more data‑driven way.

Top‑Line Decline Reflects Transition Away From COVID

Reported revenues declined modestly on an operational basis, reflecting the company’s transition away from peak pandemic economics. Full‑year 2025 revenues were $62.6 billion, down from $63.6 billion in 2024, a 2% operational decline. Q4 2025 revenues of $17.6 billion were down 3% operationally versus the prior year. Management positioned this as a reset phase, with the non‑COVID portfolio growing but not yet fully compensating for the rapid contraction in COVID products.

COVID Franchise Shrinks Sharply and Will Remain a Drag

COVID‑related revenues fell about 40% year‑over‑year in Q4 2025, driven by narrower vaccine recommendations and softer demand for Paxlovid. Pfizer expects this trend to continue, projecting roughly $5 billion in COVID revenues for 2026, well below pandemic‑era levels. While management sees COVID products as a durable but smaller business, the steep decline remains a key headwind for reported revenue growth and margins over the next several years.

Large Non‑Cash Impairments Signal Portfolio Reprioritization

Pfizer recorded approximately $4.4 billion of non‑cash intangible asset impairments in Q4 2025 tied to several development and in‑line assets. One example cited was the deprioritization of dicitamab vedotin in bladder cancer, reflecting the strong positioning of PADCEV in that setting. While these charges do not impact cash, they highlight a rigorous reprioritization of the pipeline and commercial portfolio as Pfizer reallocates capital toward assets with the highest expected return and strategic fit.

LOE Headwinds and Leverage to Stay Elevated Near Term

The company warned that LOE pressures will be a persistent drag through the 2026–2028 period. For 2026 alone, Pfizer expects roughly $1.5 billion in revenue compression from products facing generic competition. Management noted that leverage is expected to sit near 2.7x and may remain at or slightly above that level through the LOE window, reflecting acquisition‑related debt and the timing of cash flow generation. While manageable, this dynamic adds another layer of complexity to the growth and capital‑allocation narrative.

GAAP Volatility Masks Solid Adjusted Earnings

Impairments and other items created notable GAAP volatility in the quarter. Q4 2025 GAAP reported diluted EPS was a loss of $0.29 per share, largely driven by the non‑cash impairments. In contrast, adjusted diluted EPS came in at $0.66, ahead of expectations. The gap underscores the importance of distinguishing between underlying operating performance and accounting noise, a point management emphasized repeatedly to frame the company’s underlying health.

Pipeline Timing Risks Add Some Uncertainty

Management acknowledged that some event‑driven clinical readouts are progressing more slowly than anticipated, particularly certain antibody‑drug conjugate (ADC) and PD‑1 combination studies where event accrual has lagged expectations. This introduces uncertainty around the timing of near‑term catalysts, even if the scientific rationale remains intact. For investors, this may mean a more uneven flow of news and potential delays in value inflection points, though the broader pipeline remains active.

Product Mix Weighs on Quarterly Margins

While full‑year margins expanded, Q4 highlighted the challenges of shifting product mix. Adjusted gross margin in the quarter fell to around 71%, versus the mid‑to‑upper‑seventies range historically excluding COVID commodity effects. The decline primarily reflects an unfavorable mix, including lower‑margin dynamics tied to reduced COVID commodity sales. This suggests margins may remain choppy quarter‑to‑quarter as the portfolio continues to rebalance.

Guidance Reinforces Confidence in Post‑COVID Reset

Pfizer reaffirmed its full‑year 2026 guidance, calling for total revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, with an adjusted gross margin in the mid‑seventies. Management expects COVID product revenues to fall to about $5 billion and anticipates around $1.5 billion of 2026 revenue compression from generic entry. Importantly, at the midpoint of guidance, revenues excluding COVID and LOE‑impacted products are expected to grow about 4% operationally year‑over‑year. The company also reiterated its progress toward $7.2 billion in productivity savings and $5.7 billion of cost‑realignment net savings by 2026, plus $700 million of manufacturing program savings in 2026 and additional gains in 2027. With roughly $7 billion in remaining business‑development capacity, Pfizer signaled it has both the financial and operational runway to execute on its strategy.

In sum, Pfizer’s earnings call painted a picture of a company in transition but not in retreat. The drag from rapidly declining COVID revenues, LOE pressures, and large non‑cash charges is real, yet underlying non‑COVID growth, margin expansion, strong new product uptake, and a visibly productive pipeline provide a counterweight. For investors, the story now hinges on Pfizer’s ability to convert its obesity, oncology, and vaccine assets into sustained growth while executing on cost savings and AI‑driven productivity. Management’s reaffirmed 2026 guidance suggests confidence that the reset is underway and that today’s turbulence could lay the foundation for more durable earnings power beyond the LOE window.